Denali Therapeutics's total assets for Q1 2026 were $1.27B, an increase of 10.58% from the previous quarter. DNLI total liabilities were $339.93M for the fiscal quarter, a 159.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.